Biopsy-proven Histologic Scores clinical trials at University of California Health

1 research study open to eligible people

ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
open to eligible people ages 18-75
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
at UCLA

Last updated: November 5, 2025